CA3078430A1 - Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 - Google Patents

Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 Download PDF

Info

Publication number
CA3078430A1
CA3078430A1 CA3078430A CA3078430A CA3078430A1 CA 3078430 A1 CA3078430 A1 CA 3078430A1 CA 3078430 A CA3078430 A CA 3078430A CA 3078430 A CA3078430 A CA 3078430A CA 3078430 A1 CA3078430 A1 CA 3078430A1
Authority
CA
Canada
Prior art keywords
antibody
dose
subject
tumor
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078430A
Other languages
English (en)
French (fr)
Inventor
Chris Hidemi Mizufune TAKIMOTO
Mark Ping Chao
Jens-Peter VOLKMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forty Seven LLC
Original Assignee
Forty Seven LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven LLC filed Critical Forty Seven LLC
Publication of CA3078430A1 publication Critical patent/CA3078430A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3078430A 2017-10-18 2018-10-18 Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 Pending CA3078430A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574073P 2017-10-18 2017-10-18
US62/574,073 2017-10-18
PCT/US2018/056442 WO2019079549A1 (en) 2017-10-18 2018-10-18 TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1

Publications (1)

Publication Number Publication Date
CA3078430A1 true CA3078430A1 (en) 2019-04-25

Family

ID=64402251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078430A Pending CA3078430A1 (en) 2017-10-18 2018-10-18 Treatment of ovarian cancer with anti-cd47 and anti-pd-l1

Country Status (12)

Country Link
US (1) US20210047416A1 (https=)
EP (2) EP4194470A1 (https=)
JP (3) JP7308190B2 (https=)
KR (1) KR20200070341A (https=)
CN (1) CN111315783A (https=)
AU (1) AU2018351007B2 (https=)
CA (1) CA3078430A1 (https=)
ES (1) ES2938652T3 (https=)
PL (1) PL3697819T3 (https=)
PT (1) PT3697819T (https=)
SI (1) SI3697819T1 (https=)
WO (1) WO2019079549A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747906A1 (en) 2016-01-11 2020-12-09 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
SI4177270T1 (sl) 2017-10-18 2024-10-30 Forty Seven, Inc. Terapija za raka jajčnikov na osnovi sredstva proti cd47
AU2019218271B2 (en) 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
US20220289848A1 (en) * 2019-05-17 2022-09-15 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
TWI855236B (zh) * 2020-02-28 2024-09-11 大陸商南京聖和藥業股份有限公司 抗cd47/抗pd-l1抗體及其應用
JP7627349B2 (ja) * 2021-01-08 2025-02-05 北京韓美薬品有限公司 抗ｐｄ－ｌ１／抗ｃｄ４７天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
PT2970493T (pt) 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
CN117138060A (zh) * 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
BR112018005322A2 (pt) * 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
US20190290759A1 (en) * 2015-12-28 2019-09-26 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
WO2017127707A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Also Published As

Publication number Publication date
WO2019079549A1 (en) 2019-04-25
EP3697819A1 (en) 2020-08-26
EP3697819B1 (en) 2022-11-16
JP2023014162A (ja) 2023-01-26
AU2018351007A1 (en) 2020-05-21
AU2018351007B2 (en) 2024-05-16
PT3697819T (pt) 2023-02-20
JP7474827B2 (ja) 2024-04-25
KR20200070341A (ko) 2020-06-17
CN111315783A (zh) 2020-06-19
ES2938652T3 (es) 2023-04-13
EP4194470A1 (en) 2023-06-14
JP7308190B2 (ja) 2023-07-13
US20210047416A1 (en) 2021-02-18
PL3697819T3 (pl) 2023-03-06
SI3697819T1 (sl) 2023-01-31
JP2024024121A (ja) 2024-02-21
JP2021500336A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
US20250066473A1 (en) Treatment of cancer with combinations of immunoregulatory agents
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
AU2018351007B2 (en) Treatment of ovarian cancer with anti-CD47 and anti-PD-L1
EP4177270B1 (en) Anti-cd47 agent-based ovarian cancer therapy
HK40092424A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031B (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40077720A (en) Treatment of cancer with combinations of immunoregulatory agents
HK40032879A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
US9868792B2 (en) Methods of enhancing anti-tumor immunity by administering antibodies to the CCRL2 chemerin receptor
HK40043124A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40043124B (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240729

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20241028

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241128

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250616

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251209